{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T20:13:38Z","timestamp":1762546418253,"version":"build-2065373602"},"reference-count":27,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Zhejiang Province Natural Science Foundation","doi-asserted-by":"publisher","award":["LKLY25H160010"],"award-info":[{"award-number":["LKLY25H160010"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004387","name":"Ningbo University","doi-asserted-by":"publisher","award":["2024-scientific research-132"],"award-info":[{"award-number":["2024-scientific research-132"]}],"id":[{"id":"10.13039\/501100004387","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2024KY1602","2024KY1601"],"award-info":[{"award-number":["2024KY1602","2024KY1601"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jcyt.2025.05.012","type":"journal-article","created":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T11:09:40Z","timestamp":1749294580000},"page":"973-979","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of etoposide\u202f+\u202fcytarabine\u202f+\u202fpegfilgrastim mobilization regimen versus G-CSF mobilization regimen alone for hematopoietic stem cell mobilization in patients with multiple myeloma and lymphoma"],"prefix":"10.1016","volume":"27","author":[{"given":"Sishi","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yixuan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renzhi","family":"Pei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuangyue","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanhan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohong","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianxu","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haihui","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaojiao","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juntao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaolin","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peipei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2960-3131","authenticated-orcid":false,"given":"Ying","family":"lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jcyt.2025.05.012_bib0001","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jtct.2024.06.025","volume":"30","author":"Iqbal","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"10.1016\/j.jcyt.2025.05.012_bib0002","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jtct.2022.03.019","article-title":"ASTCT clinical practice recommendations for transplantation and cellular therapies in multiple myeloma","volume":"28","author":"Dhakal","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"10.1016\/j.jcyt.2025.05.012_bib0003","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1038\/bmt.2010.251","article-title":"High-dose chemotherapy with autologous stem cell rescue for relapse after allo-SCT in multiple myeloma","volume":"46","author":"Tuncer","year":"2011","journal-title":"Bone Marrow Transplant"},{"volume":"28","first-page":"1097","year":"2014","key":"10.1016\/j.jcyt.2025.05.012_bib0004"},{"issue":"24","key":"10.1016\/j.jcyt.2025.05.012_bib0005","doi-asserted-by":"crossref","DOI":"10.3390\/cells12242855","article-title":"Autologous stem cell transplant in hodgkin\u2019s and non-Hodgkin\u2019s lymphoma, multiple myeloma, and Al amyloidosis","volume":"12","author":"Alnasser","year":"2023","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.jcyt.2025.05.012_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2024.103934","article-title":"How to manage poor mobilisers","volume":"63","author":"Worel","year":"2024","journal-title":"Transfus Apher Sci"},{"issue":"7","key":"10.1016\/j.jcyt.2025.05.012_bib0007","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1002\/j.1875-9114.2012.01096.x","article-title":"Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin\u2019s lymphoma or multiple myeloma","volume":"32","author":"Lor","year":"2012","journal-title":"Pharmacotherapy"},{"issue":"6","key":"10.1016\/j.jcyt.2025.05.012_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2023.103787","article-title":"The effect of mobilizing large numbers of CD34\u202f+\u202fcells (super-mobilizers) on the engraftment and survival in patients undergoing autologous stem cell transplantation","volume":"62","author":"Moreb","year":"2023","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.jcyt.2025.05.012_bib0009","article-title":"An approach to autologous stem cell mobilization: trying to define good mobilizers","author":"Chiva","year":"2024","journal-title":"Hematol Transfus Cell Ther"},{"issue":"7","key":"10.1016\/j.jcyt.2025.05.012_bib0010","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.bbmt.2012.01.005","article-title":"Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies","volume":"18","author":"Hamadani","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jcyt.2025.05.012_bib0011","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/jca.21784","article-title":"Higher efficacy of intermediate dose cytarabine\u202f+\u202fG-CSF compared to cyclophosphamide\u202f+\u202fG-CSF in hematopoietic stem cell mobilization in patients with multiple myeloma","volume":"35","author":"Bogucka-Fedorczuk","year":"2020","journal-title":"J Clin Apher"},{"key":"10.1016\/j.jcyt.2025.05.012_bib0012","article-title":"High efficacy of stem cell mobilization with etoposide+cytarabine plus G-CSF in patients with multiple myeloma","volume":"12","author":"Zhu","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.jcyt.2025.05.012_bib0013","article-title":"Efficacy and safety of stem cell mobilization with etoposide +cytarabine plus G-CSF in poor mobilizers with relapsed or refractory lymphoma","volume":"15","author":"Zhu","year":"2024","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.jcyt.2025.05.012_bib0014","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.jcyt.2023.04.014","article-title":"Higher efficacy of etoposide\u202f+\u202fcytarabine plus pegfilgrastim in poorly mobilizing multiple myeloma and lymphoma patients","volume":"25","author":"Ye","year":"2023","journal-title":"Cytotherapy"},{"issue":"6","key":"10.1016\/j.jcyt.2025.05.012_bib0015","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1111\/bjh.19367","article-title":"Etoposide combined with cytarabine and pegfilgrastim for poorly mobilizing patients with multiple myeloma and lymphoma: a prospective multicentre study","volume":"204","author":"Ye","year":"2024","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.jcyt.2025.05.012_bib0016","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1089\/scd.1.1996.5.213","article-title":"The ISHAGE guidelines for CD34+ cell determination by flow cytometry","volume":"5","author":"Sutherland","year":"1996","journal-title":"J Hematother"},{"issue":"4","key":"10.1016\/j.jcyt.2025.05.012_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2021.103127","article-title":"Lenograstim versus filgrastim in mobilization before autologous hematopoietic stem cell transplantation in patients with multiple myeloma and lymphoma\u2014single center experience","volume":"60","author":"Sar\u0131c\u0131","year":"2021","journal-title":"Transfus Apher Sci"},{"issue":"5","key":"10.1016\/j.jcyt.2025.05.012_bib0018","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/trf.17829","article-title":"Comparison of two autologous hematopoietic stem cell mobilization strategies in patients with multiple myeloma: CE plus G-CSF versus G-CSF only: a single-center retrospective analysis","volume":"64","author":"Dill","year":"2024","journal-title":"Transfusion"},{"issue":"1","key":"10.1016\/j.jcyt.2025.05.012_bib0019","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.transci.2015.05.006","article-title":"Peripheral blood stem cell mobilization failure","volume":"53","author":"Kurnaz","year":"2015","journal-title":"Transfus Apher Sci"},{"issue":"1","key":"10.1016\/j.jcyt.2025.05.012_bib0020","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bbmt.2013.11.008","article-title":"Optimal Autologous peripheral blood progenitor cell mobilization involves more than the CD34+yield","volume":"20","author":"Fasan","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jcyt.2025.05.012_bib0021","doi-asserted-by":"crossref","first-page":"250","DOI":"10.5500\/wjt.v7.i5.250","article-title":"Peripheral blood stem cell mobilization in multiple myeloma: growth factors or chemotherapy?","volume":"7","author":"Wallis","year":"2017","journal-title":"World J Transplant"},{"issue":"10","key":"10.1016\/j.jcyt.2025.05.012_bib0022","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1038\/s41409-024-02385-1","article-title":"Mobilization strategies with and without plerixafor for autologous stem cell transplant in patients with multiple myeloma","volume":"59","author":"Avigan","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jcyt.2025.05.012_bib0023","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/jca.21360","article-title":"Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma","volume":"30","author":"Tuchman","year":"2015","journal-title":"J Clin Apher"},{"issue":"8","key":"10.1016\/j.jcyt.2025.05.012_bib0024","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/bmt.2008.369","article-title":"Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma","volume":"43","author":"Gertz","year":"2009","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jcyt.2025.05.012_bib0025","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.3109\/10428194.2015.1102240","article-title":"Selection of a mobilization regimen for multiple myeloma based on the response to induction therapy: Granulocyte-colony stimulating factor (G-CSF) alone versus high-dose cyclophosphamide plus G-CSF","volume":"57","author":"Jang","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.jcyt.2025.05.012_bib0026","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00277-016-2897-2","article-title":"Comparison of engraftment following different stem cell mobilization modalities in patients with multiple myeloma treated with a uniform induction regimen containing bortezomib, cyclophosphamide and dexamethasone","volume":"96","author":"Benyamini","year":"2017","journal-title":"Ann Hematol"},{"issue":"7","key":"10.1016\/j.jcyt.2025.05.012_bib0027","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/s41409-018-0396-x","article-title":"Cytarabine\u202f+\u202fG-CSF is more effective than cyclophosphamide\u202f+\u202fG-CSF as a stem cell mobilization regimen in multiple myeloma","volume":"54","author":"Jelinek","year":"2019","journal-title":"Bone Marrow Transplant"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324925007236?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324925007236?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T20:10:27Z","timestamp":1762546227000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324925007236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S1465324925007236"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2025.05.012","relation":{},"ISSN":["1465-3249"],"issn-type":[{"type":"print","value":"1465-3249"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of etoposide\u202f+\u202fcytarabine\u202f+\u202fpegfilgrastim mobilization regimen versus G-CSF mobilization regimen alone for hematopoietic stem cell mobilization in patients with multiple myeloma and lymphoma","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2025.05.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}